This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stasi, R. Articles by Provan, D. Search for Related Content PubMed PubMed Citation Articles by Stasi, R. Articles by Provan, D.

Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns

^a Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy; ^b Department of Hematology, University of Rome, Tor Vergata, Italy; ^c Department of Haematology, Oxford Radcliffe NHS Trust, Oxford, UK; ^d Department of Clinical Oncology, I.F.O., Rome; ^e Department of Haematology, Bart’s & The London, Queen Mary’s School of Medicine & Dentistry, London

Correspondence: Roberto Stasi, M.D., Department of Medical Sciences, Regina Apostolorum Hospital, Via S. Francesco 50, 00041 Albano Laziale, Italy. Telephone: 01139-06-932989; Fax: 01139-06-233231809; e-mail: roberto.stasi{at}uniroma2.it

The management of cancer-related anemia with erythropoietic agents presents many unresolved issues. We reviewed the literature relating to epoetin alfa (Eprex^®/Epypo^®; Ortho Biotech/Janssen-Cilag, High Wycombe, United Kingdom, http://www.orthobiotech.co.uk; Procrit^®; Ortho Biotech Products, L.P., Bridgewater, NJ, http://www.orthobiotech.com), epoetin beta (NeoRecormon^®; Hoffman-La Roche, Basel, Switzerland, http://www.roche.com), and darbepoetin alfa (Aranesp^®; Amgen Inc., Thousand Oaks, CA, http://www.amgen.com) highlighting the results of published clinical trials, safety, and cost-effectiveness. Studies were identified through MEDLINE and the bibliographies of relevant articles. Epoetin alfa, epoetin beta, and darbepoetin alfa have differing pharmacokinetic and pharmacodynamic profiles. They are all effective at reducing transfusion requirements and improving health-related quality-of-life parameters, irrespective of tumor response. A direct comparison between epoetin alfa and darbe poetin alfa is based on limited evidence, which does not allow definitive conclusions about relative efficacy and cost-effectiveness. No predictive factors for response to erythropoietic agents have been validated in prospective trials. The most consistent adverse events are thrombotic and may occur irrespective of an increase in hemoglobin. Recent research indicates that the erythropoietin receptor is expressed in several cancer cell lines, raising the concern of possible stimulation of tumor cell growth by these drugs. Studies on the cost-effectiveness of erythropoietins, particularly compared with transfusion therapy, have been challenging to conduct and analyze and have generated ambiguous results. The use of erythropoietins needs to be optimized in terms of cost-effectiveness, and issues surrounding safety need to be clarified. A stronger methodology for clinical studies and the design of new, randomized, clinical trials is a major priority.

Key Words. Cancer-related anemia • Erythropoietin • Epoetin alfa • Epoetin beta • Darbepoetin alfa • Quality of life • Fatigue • Adverse events • Cost-effectiveness

This article has been cited by other articles:

				M. Aapro, H. Ludwig, C. Bokemeyer, K. MacDonald, P. Soubeyran, M. Turner, T. Albrecht, and I. Abraham Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study Ann. Onc., October 1, 2009; 20(10): 1714 - 1721. [Abstract] [Full Text] [PDF]

				E. Spaepen, N. Demarteau, S. Van Belle, and L. Annemans Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals Oncologist, May 1, 2008; 13(5): 596 - 607. [Abstract] [Full Text] [PDF]